FGFR3 and renal pelvis/ureter urothelial carcinoma: Indeed, given the high prevalence of FGFR3 mutations and their association with a T-cell depleted phenotype in UTUC, there is a rationale for combining ICI with FGFR3 inhibitors (Figure 1).